Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 256

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 256
---
 judgment associated with the inputs used to measure their fair value. Hierarchical levels are directly related to the amount of subjectivity
with the inputs to the valuation of these assets or liabilities as follows:

| Level 1 | – | Observable inputs such as unadjusted, quoted prices in active markets for identical assets or 
 liabilities at the measurement date;                                                          |

| Level 2 | – | Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable                                     
 inputs for similar assets or liabilities. These include quoted prices for identical or similar assets or liabilities in active markets 
 and quoted prices for identical or similar assets of liabilities in markets that are not active;                                       |

| Level 3 | – | Unobservable inputs that are supported by little or no market activity and that are significant 
 to the fair value of the assets or liabilities.                                                 |

The convertible notes and warrant
liability are classified within Level 3 of the fair value hierarchy because their fair values are estimated by utilizing valuation models
and significant unobservable inputs.

| f. | Research and development expenses: |

Research and development expenses
are charged to the statements of comprehensive loss as incurred.

<div align='center'>F-9</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 2:- | SIGNIFICANT ACCOUNTING POLICIES (Cont.) |

| g. | Income taxes: |

The Company accounts for income taxes
in accordance with ASC 740, Income Taxes(“ASC 740”). ASC 740 prescribes the use of the liability method whereby deferred
tax assets and liability account balances are determined based on differences between financial reporting and tax bases of assets and
liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.
Valuation allowances in respect of deferred tax assets are provided for, if necessary, to reduce deferred tax assets to amounts more
likely than not to be realized. As of December 31, 2024 and 2023, the Company had a full valuation allowance on its deferred tax assets.

The Company implements a two-step
approach to recognize and measure uncertain tax positions. The first step is to evaluate the tax position taken or expected to be taken
in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation of
the technical merits, the